ORKA

Oruka Therapeutics, Inc.

Price Chart

Latest Quote

$85.38

+13.04 (+18.03%)

Current Price

Previous Close	$72.34
Open	$81.12
Day High	$88.83
Day Low	$79.00
Volume	4,200,169

Fetched: 2026-06-23T09:38:52

Stock Information

Shares Outstanding	60.31M
Total Debt	$1.81M
Cash Equivalents	$388.83M
Net Income	$-94.19M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$5.15B
EPS (TTM)	$-1.93
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$4.77B
Income	$-94.19M
Book/sh	$9.64
Cash/sh	$6.45
Employees	68

Financial Ratios

Quick Ratio	23.38
Current Ratio	23.76
Debt/Eq	0.37

Returns & Margins

ROA	-18.92%
ROE	-27.31%

Ownership

Insider Ownership	1.23%
Institutional Ownership	89.14%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-34.68
P/B	8.85

Analyst Data

Recommendation	strong_buy
Target Price	$142.17

Technical Indicators

SMA20	$64.13
SMA50	$65.09
SMA200	$39.05
RSI	83.89
ATR	5.1364

Shares Float	51.08M
Short Float	16.10%
Short Ratio	3.25
Rel Volume	3.20

Performance History

Week	+22.16%
Month	+40.73%
Quarter	+119.43%
6 Months	+200.85%
YTD	+202.02%
Year	+612.69%
3 Years	+548.49%
5 Years	+239.21%
10 Years	-75.58%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$85.38	4,200,300
2026-06-18	$72.34	2,986,500
2026-06-17	$70.88	769,900
2026-06-16	$67.71	816,200
2026-06-15	$68.86	1,002,300
2026-06-12	$69.89	781,500
2026-06-11	$68.47	1,188,800
2026-06-10	$64.03	1,017,100
2026-06-09	$66.93	1,566,600
2026-06-08	$64.06	1,214,000
2026-06-05	$60.14	1,301,600
2026-06-04	$62.28	1,477,700
2026-06-03	$57.20	830,000
2026-06-02	$55.23	1,161,400
2026-06-01	$55.01	1,126,400
2026-05-29	$58.53	1,229,300
2026-05-28	$57.98	618,000
2026-05-27	$57.99	671,200
2026-05-26	$59.06	1,212,300

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

📰 Latest News

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks • 2026-06-12T16:00:03Z

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Zacks • 2026-06-10T13:55:04Z

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Motley Fool • 2026-05-31T14:41:54Z

Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding

Simply Wall St. • 2026-05-15T15:18:34Z

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Motley Fool • 2026-05-13T21:06:33Z

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

Motley Fool • 2026-05-13T20:30:31Z

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally

Motley Fool • 2026-05-13T20:09:47Z

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

MT Newswires • 2026-05-12T15:54:17Z

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

Motley Fool • 2026-05-11T21:35:00Z

H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook

Insider Monkey • 2026-05-11T20:05:56Z

Period:

Income Statement (Annual)

Metric	2025-12-31
Revenue
Total Revenue	$0
Operating Revenue	$0
Expenses
Interest Expense	$0
Total Expenses	$122,051,000
Other Income Expense	$-12,000
Other Non Operating Income Expenses	$-12,000
Net Non Operating Interest Income Expense	$16,630,000
Interest Expense Non Operating	$0
Operating Expense	$122,051,000
General And Administrative Expense	$21,411,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-105,433,000
Net Interest Income	$16,630,000
Interest Income	$16,630,000
Normalized Income	$-105,433,000
Net Income From Continuing And Discontinued Operation	$-105,433,000
Total Operating Income As Reported	$-122,051,000
Net Income Common Stockholders	$-105,433,000
Net Income	$-105,433,000
Net Income Including Noncontrolling Interests	$-105,433,000
Net Income Continuous Operations	$-105,433,000
Pretax Income	$-105,433,000
Interest Income Non Operating	$16,630,000
Operating Income	$-122,051,000
Per Share
Diluted EPS	$-1.85
Basic EPS	$-1.85
Other
Tax Effect Of Unusual Items	$0
Tax Rate For Calcs	$0
Normalized EBITDA (Bullshit earnings)	$-105,350,000
Reconciled Depreciation	$83,000
EBITDA (Bullshit earnings)	$-105,350,000
EBIT	$-105,433,000
Diluted Average Shares	$45,614,142
Basic Average Shares	$45,614,142
Diluted NI Availto Com Stockholders	$-105,433,000
Research And Development	$100,640,000
Selling General And Administration	$21,411,000
Other Gand A	$6,379,000
Salaries And Wages	$15,032,000

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$468,999,000	$379,290,000
Total Assets	$488,617,000	$396,019,000
Total Non Current Assets	$144,760,000	$19,150,000
Other Non Current Assets	$103,000	$43,000
Investmentin Financial Assets	$142,539,000	$18,069,000
Current Assets	$343,857,000	$376,869,000
Other Current Assets	$6,813,000	$1,221,000
Cash Cash Equivalents And Short Term Investments	$337,044,000	$375,648,000
Cash And Cash Equivalents	$46,935,000	$61,575,000
Receivables	-	$0
Debt
Total Debt	$1,932,000	$968,000
Long Term Debt And Capital Lease Obligation	$1,313,000	$755,000
Current Debt And Capital Lease Obligation	$619,000	$213,000
Liabilities
Total Liabilities Net Minority Interest	$19,618,000	$16,729,000
Total Non Current Liabilities Net Minority Interest	$4,244,000	$3,686,000
Current Liabilities	$15,374,000	$13,043,000
Payables And Accrued Expenses	$9,489,000	$10,789,000
Payables	$4,164,000	$9,484,000
Accounts Payable	$4,155,000	$3,462,000
Equity
Common Stock Equity	$468,999,000	$379,290,000
Total Equity Gross Minority Interest	$468,999,000	$379,290,000
Stockholders Equity	$468,999,000	$379,290,000
Gains Losses Not Affecting Retained Earnings	$546,000	$-41,000
Other Equity Adjustments	$546,000	$-41,000
Retained Earnings	$-189,157,000	$-83,724,000
Preferred Securities Outside Stock Equity	$2,931,000	$2,931,000
Preferred Stock Equity	-	$2,931,000
Other
Ordinary Shares Number	$48,722,309	$37,440,510
Share Issued	$48,722,309	$37,440,510
Tangible Book Value	$468,999,000	$379,290,000
Invested Capital	$468,999,000	$379,290,000
Working Capital	$328,483,000	$363,826,000
Capital Lease Obligations	$1,932,000	$968,000
Total Capitalization	$468,999,000	$379,290,000
Additional Paid In Capital	$657,561,000	$463,018,000
Capital Stock	$49,000	$37,000
Common Stock	$49,000	$37,000
Long Term Capital Lease Obligation	$1,313,000	$755,000
Current Capital Lease Obligation	$619,000	$213,000
Pensionand Other Post Retirement Benefit Plans Current	$5,266,000	$2,041,000
Current Accrued Expenses	$5,325,000	$1,305,000
Dueto Related Parties Current	$9,000	$6,022,000
Investments And Advances	$142,539,000	$18,069,000
Available For Sale Securities	$142,539,000	$18,069,000
Net PPE	$2,118,000	$1,038,000
Gross PPE	$2,118,000	$1,038,000
Other Properties	$2,118,000	$1,038,000
Other Short Term Investments	$290,109,000	$314,073,000
Preferred Stock	-	$2,931,000

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31
Free Cash Flow
Free Cash Flow	$-88,419,000
Operating Activities
Operating Cash Flow	$-88,210,000
Cash Flow From Continuing Operating Activities	$-88,210,000
Investing Activities
Capital Expenditure	$-209,000
Investing Cash Flow	$-96,745,000
Cash Flow From Continuing Investing Activities	$-96,745,000
Financing Activities
Issuance Of Capital Stock	$671,000
Financing Cash Flow	$170,315,000
Cash Flow From Continuing Financing Activities	$170,315,000
Net Other Financing Charges	$169,644,000
Net Preferred Stock Issuance	$0
Preferred Stock Issuance	$0
Net Common Stock Issuance	$671,000
Common Stock Issuance	$671,000
Other
Issuance Of Debt	$0
End Cash Position	$46,935,000
Beginning Cash Position	$61,575,000
Changes In Cash	$-14,640,000
Net Issuance Payments Of Debt	$0
Net Long Term Debt Issuance	$0
Long Term Debt Issuance	$0
Net Investment Purchase And Sale	$-96,536,000
Sale Of Investment	$424,423,000
Purchase Of Investment	$-520,959,000
Net PPE Purchase And Sale	$-209,000
Purchase Of PPE	$-209,000
Change In Working Capital	$-2,555,000
Change In Other Current Liabilities	$-448,000
Change In Other Current Assets	$-60,000
Change In Payables And Accrued Expense	$1,925,000
Change In Accrued Expense	$7,245,000
Change In Payable	$-5,320,000
Change In Account Payable	$-5,320,000
Change In Prepaid Assets	$-3,972,000
Other Non Cash Items	$-4,545,000
Stock Based Compensation	$24,240,000
Depreciation Amortization Depletion	$83,000
Depreciation And Amortization	$83,000
Depreciation	$83,000
Net Income From Continuing Operations	$-105,433,000

Fetched: 2026-06-22